WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Xinhua Commentary: Xi's Meeting with Ma Injects Positive Energy to Relations Across Taiwan StraitPainting new picture for Asian Games, creating better future for AsiaBreaking through barriersNanjing Railway Station experienced a small peak of passenger flow in weekend3rd Belt and Road Forum will be a landmark event: Pakistani expertHow APEC meetings turn out is a test for the USFamily of heiress who drowned are to sue her husband who was accused of killing her3rd Belt and Road Forum will be a landmark event: Pakistani expertForeign specialties set up stalls at China International Fair for Trade in ServicesBRI promotes modernization, mutual benefit